Your browser doesn't support javascript.
loading
Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy.
Vigneron, Nicolas; Meryet-Figuière, Matthieu; Guttin, Audrey; Issartel, Jean-Paul; Lambert, Bernard; Briand, Mélanie; Louis, Marie-Hélène; Vernon, Mégane; Lebailly, Pierre; Lecluse, Yannick; Joly, Florence; Krieger, Sophie; Lheureux, Stéphanie; Clarisse, Bénédicte; Leconte, Alexandra; Gauduchon, Pascal; Poulain, Laurent; Denoyelle, Christophe.
Affiliation
  • Vigneron N; Inserm U1199, « Biology and Innovative Therapeutics for Locally Aggressive Cancer ¼ (BioTICLA) Unit, Caen, France; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France.
  • Meryet-Figuière M; Inserm U1199, « Biology and Innovative Therapeutics for Locally Aggressive Cancer ¼ (BioTICLA) Unit, Caen, France; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France.
  • Guttin A; EPHE, Inserm U823, CaCys, Grenoble, France.
  • Issartel JP; Inserm U1216, Transcriptomics Core Facility, Grenoble, France; Univ. Grenoble Alpes, GIN, Grenoble, France.
  • Lambert B; Inserm U1199, « Biology and Innovative Therapeutics for Locally Aggressive Cancer ¼ (BioTICLA) Unit, Caen, France; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France; CNRS, France.
  • Briand M; Inserm U1199, « Biology and Innovative Therapeutics for Locally Aggressive Cancer ¼ (BioTICLA) Unit, Caen, France; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France.
  • Louis MH; Inserm U1199, « Biology and Innovative Therapeutics for Locally Aggressive Cancer ¼ (BioTICLA) Unit, Caen, France; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France.
  • Vernon M; Inserm U1199, « Biology and Innovative Therapeutics for Locally Aggressive Cancer ¼ (BioTICLA) Unit, Caen, France; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France.
  • Lebailly P; Inserm U1086, Cancers & Preventions, Caen, France.
  • Lecluse Y; Inserm U1086, Cancers & Preventions, Caen, France.
  • Joly F; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France; Inserm U1086, Cancers & Preventions, Caen, France; Medical Oncology Department, Comprehensive Cancer Center F. Baclesse, Caen, France; Clinical Research Department, Comprehensive Cancer Cen
  • Krieger S; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France; Biopathology Department, Comprehensive Cancer Center F. Baclesse, Caen, France; Inserm U1079, Institute for Research and Innovation in Biomedicine, University of Rouen, Rouen, France.
  • Lheureux S; Inserm U1199, « Biology and Innovative Therapeutics for Locally Aggressive Cancer ¼ (BioTICLA) Unit, Caen, France; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France; Medical Oncology Department, Comprehensive Cancer Center F. Baclesse, Caen, Fr
  • Clarisse B; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France; Clinical Research Department, Comprehensive Cancer Center F. Baclesse, Caen, France.
  • Leconte A; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France; Clinical Research Department, Comprehensive Cancer Center F. Baclesse, Caen, France.
  • Gauduchon P; Inserm U1199, « Biology and Innovative Therapeutics for Locally Aggressive Cancer ¼ (BioTICLA) Unit, Caen, France; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France.
  • Poulain L; Inserm U1199, « Biology and Innovative Therapeutics for Locally Aggressive Cancer ¼ (BioTICLA) Unit, Caen, France; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France.
  • Denoyelle C; Inserm U1199, « Biology and Innovative Therapeutics for Locally Aggressive Cancer ¼ (BioTICLA) Unit, Caen, France; Normandie Univ, France; UNICAEN, France; Comprehensive Cancer Center F. Baclesse, Unicancer, Caen, France. Electronic address: c.denoyelle@baclesse.unicancer.fr.
Mol Oncol ; 10(7): 981-92, 2016 08.
Article in En | MEDLINE | ID: mdl-27083764
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Expression Profiling / MicroRNAs Type of study: Prognostic_studies Limits: Humans Language: En Journal: Mol Oncol Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2016 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Expression Profiling / MicroRNAs Type of study: Prognostic_studies Limits: Humans Language: En Journal: Mol Oncol Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2016 Document type: Article Affiliation country: Country of publication: